{ "ticker": "ABT", "cik": "0000001800", "company": "Abbott Laboratories", "business_type": "industrial", "schema_template": "standard (revenue / operating earnings / net earnings; balance sheet; cash flow)", "schema_rationale": "Abbott is a diversified healthcare products manufacturer selling branded generic pharmaceuticals, nutritionals, diagnostics and medical devices. The standard manufacturer template fits: net sales, cost of products sold, operating earnings, net earnings and per-share amounts, with a balance sheet and a cash flow statement. Abbott reports cost of products sold EXCLUDING amortization of acquired intangibles and does not print a gross profit line, so none is stated here; the two cost lines are reported separately exactly as the filings present them. Segment net sales and segment operating earnings are carried alongside because Abbott manages and reports the business in four segments.", "reporting_currency": "USD", "converted_to_usd": false, "units": "actual dollars (not millions)", "fiscal_calendar_note": "Abbott's fiscal year is the calendar year, ending December 31. Quarters end March 31, June 30, September 30 and December 31.", "units_notes_seen": { "FY2025 10-K consolidated statement of earnings": "(in millions except per share data)", "FY2025 10-K consolidated statement of comprehensive income": "(in millions)", "FY2025 10-K consolidated statement of cash flows": "(in millions)", "FY2025 10-K consolidated balance sheet": "(dollars in millions)", "FY2025 10-K segment information (Note 16)": "(in millions)", "Q2 2026 10-Q condensed consolidated statement of earnings": "(dollars in millions except per share data; shares in thousands)", "Q2 2026 10-Q condensed consolidated balance sheet": "(dollars in millions)", "Q2 2026 10-Q condensed consolidated statement of cash flows": "(dollars in millions)", "Q2 2026 10-Q segment information (Note 15)": "(in millions)", "Q2 2026 10-Q business acquisition purchase price allocation (Note 6)": "(in billions)" }, "adjustments": { "splits_applied": [], "adr_ratio": null, "fx": "None. Abbott reports in U.S. dollars, so no currency conversion was applied." }, "annual": [ { "fiscal_year": 2025, "label": "FY2025", "period_start": "2025-01-01", "period_end": "2025-12-31", "period_type": "fiscal year", "source_accession": "0001628280-26-010185", "source_form": "10-K filed 2026-02-20", "income_statement": { "net_sales": 44328000000, "cost_of_products_sold_excluding_amortization": 19319000000, "amortization_of_intangible_assets": 1682000000, "research_and_development": 2942000000, "selling_general_and_administrative": 12332000000, "total_operating_cost_and_expenses": 36275000000, "operating_earnings": 8053000000, "interest_expense": 493000000, "interest_income": -308000000, "net_foreign_exchange_gain_loss": -50000000, "other_income_expense_net": -548000000, "earnings_before_taxes": 8466000000, "taxes_on_earnings": 1942000000, "net_earnings": 6524000000, "basic_eps": 3.73, "diluted_eps": 3.72, "basic_shares": 1741000000, "diluted_shares": 1748000000 }, "segment_results": { "established_pharmaceuticals": { "net_sales": 5536000000, "operating_earnings": 1290000000 }, "nutritional_products": { "net_sales": 8451000000, "operating_earnings": 1558000000 }, "diagnostic_products": { "net_sales": 8937000000, "operating_earnings": 1740000000 }, "medical_devices": { "net_sales": 21387000000, "operating_earnings": 7212000000 }, "total_reportable_segments": { "net_sales": 44311000000, "operating_earnings": 11800000000 } }, "balance_sheet": { "cash_and_equivalents": 8522000000, "short_term_investments": 417000000, "trade_receivables_net": 7929000000, "total_inventories": 6488000000, "total_current_assets": 25996000000, "net_property_and_equipment": 11816000000, "intangible_assets_net": 5526000000, "goodwill": 24035000000, "total_assets": 86713000000, "current_portion_of_long_term_debt": 3033000000, "total_current_liabilities": 16496000000, "long_term_debt": 9896000000, "post_employment_and_other_long_term_liabilities": 7550000000, "total_abbott_shareholders_investment": 52130000000, "noncontrolling_interests": 641000000, "total_equity": 52771000000, "total_debt": 12929000000, "total_liabilities": 33942000000 }, "cash_flow": { "depreciation": 1434000000, "amortization_of_intangible_assets": 1682000000, "share_based_compensation": 664000000, "operating_cash_flow": 9566000000, "acquisitions_of_businesses_and_technologies_net_of_cash": -105000000, "investing_cash_flow": -2422000000, "financing_cash_flow": -6309000000, "cash_and_equivalents_end_of_period": 8522000000, "capital_expenditures": 2171000000, "dividends_paid": 4116000000, "purchases_of_common_shares": 893000000, "free_cash_flow": 7395000000 } }, { "fiscal_year": 2024, "label": "FY2024", "period_start": "2024-01-01", "period_end": "2024-12-31", "period_type": "fiscal year", "source_accession": "0001628280-26-010185", "source_form": "10-K filed 2026-02-20", "income_statement": { "net_sales": 41950000000, "cost_of_products_sold_excluding_amortization": 18706000000, "amortization_of_intangible_assets": 1878000000, "research_and_development": 2844000000, "selling_general_and_administrative": 11697000000, "total_operating_cost_and_expenses": 35125000000, "operating_earnings": 6825000000, "interest_expense": 559000000, "interest_income": -344000000, "net_foreign_exchange_gain_loss": -27000000, "other_income_expense_net": -376000000, "earnings_before_taxes": 7013000000, "taxes_on_earnings": -6389000000, "net_earnings": 13402000000, "basic_eps": 7.67, "diluted_eps": 7.64, "basic_shares": 1740000000, "diluted_shares": 1748000000 }, "segment_results": { "established_pharmaceuticals": { "net_sales": 5194000000, "operating_earnings": 1233000000 }, "nutritional_products": { "net_sales": 8413000000, "operating_earnings": 1505000000 }, "diagnostic_products": { "net_sales": 9341000000, "operating_earnings": 2073000000 }, "medical_devices": { "net_sales": 18986000000, "operating_earnings": 6153000000 }, "total_reportable_segments": { "net_sales": 41934000000, "operating_earnings": 10964000000 } }, "balance_sheet": { "cash_and_equivalents": 7616000000, "short_term_investments": 351000000, "trade_receivables_net": 6925000000, "total_inventories": 6194000000, "total_current_assets": 23656000000, "net_property_and_equipment": 10658000000, "intangible_assets_net": 6647000000, "goodwill": 23108000000, "total_assets": 81414000000, "current_portion_of_long_term_debt": 1500000000, "total_current_liabilities": 14157000000, "long_term_debt": 12625000000, "post_employment_and_other_long_term_liabilities": 6731000000, "total_abbott_shareholders_investment": 47664000000, "noncontrolling_interests": 237000000, "total_equity": 47901000000, "total_debt": 14125000000, "total_liabilities": 33513000000 }, "cash_flow": { "depreciation": 1340000000, "amortization_of_intangible_assets": 1878000000, "share_based_compensation": 673000000, "operating_cash_flow": 8558000000, "acquisitions_of_businesses_and_technologies_net_of_cash": 0, "investing_cash_flow": -2338000000, "financing_cash_flow": -5404000000, "cash_and_equivalents_end_of_period": 7616000000, "capital_expenditures": 2207000000, "dividends_paid": 3836000000, "purchases_of_common_shares": 1295000000, "free_cash_flow": 6351000000 } }, { "fiscal_year": 2023, "label": "FY2023", "period_start": "2023-01-01", "period_end": "2023-12-31", "period_type": "fiscal year", "source_accession": "0001628280-26-010185", "source_form": "10-K filed 2026-02-20", "income_statement": { "net_sales": 40109000000, "cost_of_products_sold_excluding_amortization": 17975000000, "amortization_of_intangible_assets": 1966000000, "research_and_development": 2741000000, "selling_general_and_administrative": 10949000000, "total_operating_cost_and_expenses": 33631000000, "operating_earnings": 6478000000, "interest_expense": 637000000, "interest_income": -385000000, "net_foreign_exchange_gain_loss": 41000000, "other_income_expense_net": -479000000, "earnings_before_taxes": 6664000000, "taxes_on_earnings": 941000000, "net_earnings": 5723000000, "basic_eps": 3.28, "diluted_eps": 3.26, "basic_shares": 1740000000, "diluted_shares": 1749000000 }, "segment_results": { "established_pharmaceuticals": { "net_sales": 5066000000, "operating_earnings": 1206000000 }, "nutritional_products": { "net_sales": 8154000000, "operating_earnings": 1333000000 }, "diagnostic_products": { "net_sales": 9988000000, "operating_earnings": 2433000000 }, "medical_devices": { "net_sales": 16887000000, "operating_earnings": 5306000000 }, "total_reportable_segments": { "net_sales": 40095000000, "operating_earnings": 10278000000 } }, "cash_flow": { "depreciation": 1277000000, "amortization_of_intangible_assets": 1966000000, "share_based_compensation": 644000000, "operating_cash_flow": 7261000000, "acquisitions_of_businesses_and_technologies_net_of_cash": -877000000, "investing_cash_flow": -3133000000, "financing_cash_flow": -7091000000, "cash_and_equivalents_end_of_period": 6896000000, "capital_expenditures": 2202000000, "dividends_paid": 3556000000, "purchases_of_common_shares": 1227000000, "free_cash_flow": 5059000000 } } ], "quarterly": [ { "fiscal_year": 2026, "fiscal_quarter": 2, "label": "Q2 2026", "period_start": "2026-04-01", "period_end": "2026-06-30", "period_type": "three months", "source_accession": "0001628280-26-050134", "source_form": "10-Q filed 2026-07-28", "income_statement": { "net_sales": 12593000000, "cost_of_products_sold_excluding_amortization": 5325000000, "amortization_of_intangible_assets": 658000000, "research_and_development": 892000000, "selling_general_and_administrative": 4025000000, "total_operating_cost_and_expenses": 10900000000, "operating_earnings": 1693000000, "interest_expense": 351000000, "interest_income": -52000000, "net_foreign_exchange_gain_loss": 4000000, "other_income_expense_net": -134000000, "earnings_before_taxes": 1524000000, "taxes_on_earnings": 596000000, "net_earnings": 928000000, "basic_eps": 0.53, "diluted_eps": 0.53, "basic_shares": 1740420000, "diluted_shares": 1742981000 }, "segment_results": { "established_pharmaceuticals": { "net_sales": 1499000000, "operating_earnings": 382000000 }, "nutritional_products": { "net_sales": 2144000000, "operating_earnings": 368000000 }, "diagnostic_products": { "net_sales": 3092000000, "operating_earnings": 499000000 }, "medical_devices": { "net_sales": 5853000000, "operating_earnings": 1969000000 }, "total_reportable_segments": { "net_sales": 12588000000, "operating_earnings": 3218000000 } }, "balance_sheet": { "cash_and_equivalents": 5104000000, "short_term_investments": 499000000, "trade_receivables_net": 8599000000, "total_inventories": 7315000000, "total_current_assets": 24517000000, "net_property_and_equipment": 12812000000, "intangible_assets_net": 17211000000, "goodwill": 35244000000, "total_assets": 109215000000, "current_portion_of_long_term_debt": 3005000000, "total_current_liabilities": 17814000000, "long_term_debt": 29603000000, "post_employment_and_other_long_term_liabilities": 10036000000, "total_abbott_shareholders_investment": 51110000000, "noncontrolling_interests": 652000000, "total_equity": 51762000000, "total_debt": 32608000000, "total_liabilities": 57453000000 } }, { "fiscal_year": 2025, "fiscal_quarter": 2, "label": "Q2 2025", "period_start": "2025-04-01", "period_end": "2025-06-30", "period_type": "three months", "source_accession": "0001628280-26-050134", "source_form": "10-Q filed 2026-07-28", "income_statement": { "net_sales": 11142000000, "cost_of_products_sold_excluding_amortization": 4854000000, "amortization_of_intangible_assets": 420000000, "research_and_development": 725000000, "selling_general_and_administrative": 3091000000, "total_operating_cost_and_expenses": 9090000000, "operating_earnings": 2052000000, "interest_expense": 121000000, "interest_income": -71000000, "net_foreign_exchange_gain_loss": -11000000, "other_income_expense_net": -137000000, "earnings_before_taxes": 2150000000, "taxes_on_earnings": 371000000, "net_earnings": 1779000000, "basic_eps": 1.02, "diluted_eps": 1.01, "basic_shares": 1743437000, "diluted_shares": 1750835000 }, "segment_results": { "established_pharmaceuticals": { "net_sales": 1383000000, "operating_earnings": 346000000 }, "nutritional_products": { "net_sales": 2212000000, "operating_earnings": 418000000 }, "diagnostic_products": { "net_sales": 2173000000, "operating_earnings": 372000000 }, "medical_devices": { "net_sales": 5369000000, "operating_earnings": 1796000000 }, "total_reportable_segments": { "net_sales": 11137000000, "operating_earnings": 2932000000 } } } ], "year_to_date": { "label": "Six months ended June 30, 2026", "period_start": "2026-01-01", "period_end": "2026-06-30", "period_type": "six months", "source_accession": "0001628280-26-050134", "source_form": "10-Q filed 2026-07-28", "income_statement": { "net_sales": 23757000000, "cost_of_products_sold_excluding_amortization": 10215000000, "amortization_of_intangible_assets": 1080000000, "research_and_development": 1659000000, "selling_general_and_administrative": 7765000000, "total_operating_cost_and_expenses": 20719000000, "operating_earnings": 3038000000, "interest_expense": 525000000, "interest_income": -158000000, "net_foreign_exchange_gain_loss": -9000000, "other_income_expense_net": -293000000, "earnings_before_taxes": 2973000000, "taxes_on_earnings": 968000000, "net_earnings": 2005000000, "basic_eps": 1.15, "diluted_eps": 1.14, "basic_shares": 1741438000, "diluted_shares": 1745014000 }, "segment_results": { "established_pharmaceuticals": { "net_sales": 2925000000, "operating_earnings": 747000000 }, "nutritional_products": { "net_sales": 4161000000, "operating_earnings": 679000000 }, "diagnostic_products": { "net_sales": 5272000000, "operating_earnings": 834000000 }, "medical_devices": { "net_sales": 11392000000, "operating_earnings": 3862000000 }, "total_reportable_segments": { "net_sales": 23750000000, "operating_earnings": 6122000000 } }, "cash_flow": { "operating_cash_flow": 3803000000, "capital_expenditures": 896000000, "acquisitions_of_businesses_and_technologies_net_of_cash": -19962000000, "investing_cash_flow": -20997000000, "financing_cash_flow": 13795000000, "dividends_paid": 2200000000, "purchases_of_common_shares": 1225000000, "depreciation": 783000000, "amortization_of_intangible_assets": 1080000000, "share_based_compensation": 485000000, "cash_and_equivalents_end_of_period": 5104000000, "free_cash_flow": 2907000000 }, "prior_year_comparative": { "label": "Six months ended June 30, 2025", "period_start": "2025-01-01", "period_end": "2025-06-30", "period_type": "six months", "source_accession": "0001628280-26-050134", "source_form": "10-Q filed 2026-07-28", "income_statement": { "net_sales": 21500000000, "cost_of_products_sold_excluding_amortization": 9322000000, "amortization_of_intangible_assets": 840000000, "research_and_development": 1441000000, "selling_general_and_administrative": 6152000000, "total_operating_cost_and_expenses": 17755000000, "operating_earnings": 3745000000, "interest_expense": 252000000, "interest_income": -153000000, "net_foreign_exchange_gain_loss": -18000000, "other_income_expense_net": -264000000, "earnings_before_taxes": 3928000000, "taxes_on_earnings": 824000000, "net_earnings": 3104000000, "basic_eps": 1.78, "diluted_eps": 1.77, "basic_shares": 1741348000, "diluted_shares": 1749054000 }, "segment_results": { "established_pharmaceuticals": { "net_sales": 2643000000, "operating_earnings": 644000000 }, "nutritional_products": { "net_sales": 4358000000, "operating_earnings": 812000000 }, "diagnostic_products": { "net_sales": 4227000000, "operating_earnings": 731000000 }, "medical_devices": { "net_sales": 10264000000, "operating_earnings": 3405000000 }, "total_reportable_segments": { "net_sales": 21492000000, "operating_earnings": 5592000000 } }, "cash_flow": { "operating_cash_flow": 3464000000, "capital_expenditures": 986000000, "acquisitions_of_businesses_and_technologies_net_of_cash": -30000000, "investing_cash_flow": -1052000000, "financing_cash_flow": -3152000000, "dividends_paid": 2055000000, "purchases_of_common_shares": 286000000, "depreciation": 693000000, "amortization_of_intangible_assets": 840000000, "share_based_compensation": 431000000, "cash_and_equivalents_end_of_period": 6951000000, "free_cash_flow": 2478000000 } } }, "trailing_twelve_months": { "label": "Trailing twelve months ended June 30, 2026", "period_start": "2025-07-01", "period_end": "2026-06-30", "period_type": "trailing twelve months", "source_accession": "0001628280-26-050134", "source_form": "derived from the 10-Q filed 2026-07-28 and the 10-K filed 2026-02-20", "income_statement": { "net_sales": 46585000000, "cost_of_products_sold_excluding_amortization": 20212000000, "amortization_of_intangible_assets": 1922000000, "research_and_development": 3160000000, "selling_general_and_administrative": 13945000000, "total_operating_cost_and_expenses": 39239000000, "operating_earnings": 7346000000, "interest_expense": 766000000, "interest_income": -313000000, "net_foreign_exchange_gain_loss": -41000000, "other_income_expense_net": -577000000, "earnings_before_taxes": 7511000000, "taxes_on_earnings": 2086000000, "net_earnings": 5425000000, "diluted_shares": 1745980000, "diluted_eps": 3.11 }, "cash_flow": { "operating_cash_flow": 9905000000, "capital_expenditures": 2081000000, "dividends_paid": 4261000000, "purchases_of_common_shares": 1832000000, "depreciation": 1524000000, "free_cash_flow": 7824000000 } }, "notes": [ "Annual figures for 2025, 2024 and 2023 come from Abbott's Form 10-K for the year ended December 31, 2025 (accession 0001628280-26-010185). That filing's statement of earnings and statement of cash flows each present three years; the balance sheet presents only December 31, 2025 and December 31, 2024. FY2023 therefore carries an income statement and a cash flow statement here but no balance sheet.", "Quarterly, six-month and June 30, 2026 balance sheet figures come from Abbott's Form 10-Q for the quarter ended June 30, 2026 (accession 0001628280-26-050134). The quarterly list holds only the two discrete three-month periods that filing prints (the second quarter of 2026 and the second quarter of 2025); its six-month columns are kept separately under year_to_date so a cumulative figure is never read as a quarter. The 10-Q presents a balance sheet only at June 30, 2026 (with December 31, 2025 as the comparative), so the second quarter of 2025 carries no balance sheet.", "Abbott reports cost of products sold EXCLUDING amortization of intangible assets, and presents no gross profit subtotal. None is stated here; the two cost lines are carried separately, exactly as the statements print them.", "Abbott presents interest expense, interest (income), net foreign exchange (gain) loss and other (income) expense, net as deductions inside the expense stack below operating earnings, printing income amounts in parentheses. Those lines are carried here on that same basis, so a negative value denotes income: interest_income of -$308 million for fiscal 2025 and -$52 million for the second quarter of 2026 each mean interest INCOME of that amount, not a loss. Keeping the filing's signs is what lets operating earnings less these four lines reconcile to earnings before taxes in every period shown.", "Abbott's balance sheet prints no total liabilities line. The total liabilities figure here is the sum of total current liabilities, long-term debt, and post-employment obligations, deferred income taxes and other long-term liabilities; it ties to total assets less total shareholders' investment in each period shown. Total debt is the current portion of long-term debt plus long-term debt, as printed on the balance sheet.", "Abbott publishes no free cash flow figure. Free cash flow here is net cash from operating activities less acquisitions of property and equipment, which is the only capital expenditure line the cash flow statements show.", "The 10-Q's cash flow statement is presented for the six months ended June 30 only, and Abbott's second-quarter earnings release contains no cash flow statement. No discrete three-month cash flow is published, so neither quarterly entry carries a cash flow block; the six-month cash flows sit under year_to_date.", "The trailing-twelve-month view is derived, not filed: fiscal 2025 plus the six months ended June 30, 2026, less the six months ended June 30, 2025. Its diluted EPS is trailing net earnings divided by an implied trailing weighted average diluted share count of about 1,746.0 million, rolled forward the same way. Abbott does not publish either figure.", "On March 23, 2026, Abbott completed the acquisition of Exact Sciences Corporation for approximately $20.6 billion, paying $105 per share in cash, funded primarily by $20.0 billion of long-term debt issued in March 2026. The purchase price allocation is preliminary. This is what moves the June 30, 2026 balance sheet against December 31, 2025: goodwill from $24.0 billion to $35.2 billion, intangible assets from $5.5 billion to $17.2 billion and long-term debt from $9.9 billion to $29.6 billion, with $19,962 million of acquisitions of businesses and technologies in investing activities for the six months. Abbott also assumed about $2.8 billion of Exact Sciences debt, nearly all repaid by June 30, 2026. Exact Sciences contributed roughly $1.0 billion of net sales in the first six months of 2026 and is reported inside the Diagnostic Products segment as Cancer Diagnostics.", "Second-quarter 2026 net sales rose 13.0 percent from a year earlier while net earnings fell to $928 million from $1,779 million. On the face of the statement of earnings the cost lines that moved most were amortization of intangible assets ($658 million against $420 million), selling, general and administrative expense ($4,025 million against $3,091 million) and interest expense ($351 million against $121 million). The 10-Q attributes the rise in interest expense primarily to interest on debt incurred for the Exact Sciences acquisition.", "Fiscal 2024's taxes on earnings is a net BENEFIT of $6,389 million rather than an expense, which is why FY2024 net earnings of $13,402 million exceed pre-tax earnings of $7,013 million. The 10-K attributes this to $7.5 billion of non-cash valuation allowance adjustments following the restructuring of certain foreign affiliates and the confirmation of certain tax filing positions. FY2024 net earnings and EPS are not comparable with FY2023 or FY2025 on that basis.", "Segment figures are prepared on Abbott's internal management-reporting basis and are explicitly not presented in accordance with generally accepted accounting principles. Segment operating earnings exclude intangible asset amortization, corporate functions and benefit costs, net interest, share-based compensation and other net items, so they do not sum to consolidated operating earnings. Reportable-segment net sales also exclude a small 'Other' amount ($17 million in 2025; $5 million in the second quarter of 2026), so the segment total sits just below consolidated net sales.", "Share counts are recorded in actual shares. The 10-K's statement of earnings states shares in millions and the 10-Q's states them in thousands; both were converted here.", "No stock split, currency conversion or ADS adjustment applies. Abbott has not split its common stock in the years covered here, reports in U.S. dollars, and is a domestic filer whose common shares trade directly." ], "uncertainties": [ "No discrete three-month cash flow figure exists for either quarter shown. Abbott's 10-Q presents cash flows cumulatively for the six months, and the second-quarter earnings release furnished on Form 8-K contains no cash flow statement. A quarterly operating or free cash flow figure could not be read from any filing and is therefore absent rather than estimated.", "The Exact Sciences purchase price allocation is described in the 10-Q as preliminary, and the filing states that differences between the preliminary and final allocation could be material. The goodwill, intangible assets and deferred tax amounts on the June 30, 2026 balance sheet may change as the valuation is completed, which would also change future amortization.", "The trailing-twelve-month block is a roll-forward, not a reported period. Its diluted EPS in particular rests on an implied weighted average share count rather than one Abbott published, and small differences from a figure computed a different way should be expected.", "The June 30, 2026 balance sheet and all 2026 quarterly figures are unaudited and condensed, as the 10-Q states." ], "headline": { "period": "Q2 FY2026", "period_end_words": "June 30, 2026", "metrics": [ { "label": "Revenue", "format": "usd", "value": 12593000000, "text": "$12.59 billion", "exact": "$12,593,000,000", "compact": "$12.59B", "abs": "$12.59 billion", "prior_value": 11142000000, "prior": "$11.14 billion", "priorabs": "$11.14 billion", "yoy": "up 13.0%", "source": { "array": "quarterly", "field": "income_statement.net_sales", "index": 0, "period_label": "Q2 2026", "period_end": "2026-06-30", "period_start": "2026-04-01", "span_days": 90, "source_accession": "0001628280-26-050134", "prior_index": 1, "prior_period_label": "Q2 2025", "prior_period_end": "2025-06-30", "prior_period_start": "2025-04-01", "prior_span_days": 90, "prior_source_accession": "0001628280-26-050134", "gap_days": 365 } }, { "label": "Net income", "format": "usd", "value": 928000000, "text": "$928 million", "exact": "$928,000,000", "compact": "$928.00M", "abs": "$928 million", "prior_value": 1779000000, "prior": "$1.78 billion", "priorabs": "$1.78 billion", "yoy": "down 47.8%", "source": { "array": "quarterly", "field": "income_statement.net_earnings", "index": 0, "period_label": "Q2 2026", "period_end": "2026-06-30", "period_start": "2026-04-01", "span_days": 90, "source_accession": "0001628280-26-050134", "prior_index": 1, "prior_period_label": "Q2 2025", "prior_period_end": "2025-06-30", "prior_period_start": "2025-04-01", "prior_span_days": 90, "prior_source_accession": "0001628280-26-050134", "gap_days": 365 } }, { "label": "Diluted EPS", "format": "eps", "value": 0.53, "text": "$0.53", "exact": "$0.53", "compact": "$0.53", "abs": "$0.53", "prior_value": 1.01, "prior": "$1.01", "priorabs": "$1.01", "yoy": "down 47.5%", "source": { "array": "quarterly", "field": "income_statement.diluted_eps", "index": 0, "period_label": "Q2 2026", "period_end": "2026-06-30", "period_start": "2026-04-01", "span_days": 90, "source_accession": "0001628280-26-050134", "prior_index": 1, "prior_period_label": "Q2 2025", "prior_period_end": "2025-06-30", "prior_period_start": "2025-04-01", "prior_span_days": 90, "prior_source_accession": "0001628280-26-050134", "gap_days": 365 } }, { "label": "Operating earnings", "format": "usd", "value": 1693000000, "text": "$1.69 billion", "exact": "$1,693,000,000", "compact": "$1.69B", "abs": "$1.69 billion", "prior_value": 2052000000, "prior": "$2.05 billion", "priorabs": "$2.05 billion", "yoy": "down 17.5%", "source": { "array": "quarterly", "field": "income_statement.operating_earnings", "index": 0, "period_label": "Q2 2026", "period_end": "2026-06-30", "period_start": "2026-04-01", "span_days": 90, "source_accession": "0001628280-26-050134", "prior_index": 1, "prior_period_label": "Q2 2025", "prior_period_end": "2025-06-30", "prior_period_start": "2025-04-01", "prior_span_days": 90, "prior_source_accession": "0001628280-26-050134", "gap_days": 365 } }, { "label": "Medical Devices sales", "format": "usd", "value": 5853000000, "text": "$5.85 billion", "exact": "$5,853,000,000", "compact": "$5.85B", "abs": "$5.85 billion", "prior_value": 5369000000, "prior": "$5.37 billion", "priorabs": "$5.37 billion", "yoy": "up 9.0%", "source": { "array": "quarterly", "field": "segment_results.medical_devices.net_sales", "index": 0, "period_label": "Q2 2026", "period_end": "2026-06-30", "period_start": "2026-04-01", "span_days": 90, "source_accession": "0001628280-26-050134", "prior_index": 1, "prior_period_label": "Q2 2025", "prior_period_end": "2025-06-30", "prior_period_start": "2025-04-01", "prior_span_days": 90, "prior_source_accession": "0001628280-26-050134", "gap_days": 365 } } ], "summary": "Abbott Laboratories reported $12.59 billion in net sales for Q2 FY2026, the quarter ended June 30, 2026, up 13.0% from a year earlier, as the Exact Sciences cancer diagnostics business acquired in March 2026 added to the Diagnostic Products segment. Earnings moved the other way: net earnings were $928 million, down 47.8%, and diluted EPS was $0.53 against $1.01 a year earlier, with acquisition-related intangible amortization, integration expense, higher legal reserves, interest on the debt raised for the acquisition and a higher tax charge all weighing on the result. Operating earnings were $1.69 billion, down 17.5%, while Medical Devices, Abbott's largest segment, had sales of $5.85 billion, up 9.0%.", "qa": [ { "q": "How much revenue did Abbott report in Q2 FY2026?", "a": "Abbott Laboratories reported $12.59 billion in net sales for Q2 FY2026, the quarter ended June 30, 2026. That is up 13.0% from $11.14 billion in the same quarter a year earlier, growth that includes the Exact Sciences business acquired in March 2026." }, { "q": "What was Abbott's earnings per share in Q2 FY2026?", "a": "Abbott Laboratories reported diluted earnings per share of $0.53 for Q2 FY2026, the quarter ended June 30, 2026, against $1.01 in the same quarter a year earlier. Net earnings for the quarter were $928 million, down 47.8%." }, { "q": "Why did Abbott's profit fall in Q2 FY2026?", "a": "Abbott Laboratories earned $928 million in Q2 FY2026, down 47.8% from $1.78 billion a year earlier, even though net sales rose. Operating earnings were $1.69 billion, down 17.5%, held back by intangible amortization and integration expense from the Exact Sciences acquisition and by higher legal reserves, and the rest of the decline came below the operating line from interest on the acquisition debt and a higher tax charge." }, { "q": "How much did Abbott's Medical Devices segment sell in Q2 FY2026?", "a": "Abbott Laboratories' Medical Devices segment, its largest business, had net sales of $5.85 billion in Q2 FY2026, the quarter ended June 30, 2026, up 9.0% from $5.37 billion a year earlier." } ] }, "company_details": { "Name": "Abbott Laboratories", "Ticker": "ABT", "CIK": "0000001800", "Exchange": "NYSE", "State": "Illinois", "Incorporation": "Illinois", "SIC": "2834", "Office": "Life Sciences", "Industry": "Pharmaceutical Preparations" }, "next_filing": { "predicted_date": "2026-10-28", "predicted_type": "10-Q" }, "fiscal_period": { "fiscal_year": 2026, "fiscal_period": "Q2", "tag": "FY26Q2", "period_end": "2026-06-30", "form": "10-Q", "accession": "0001628280-26-050134", "fiscal_year_end": "1231", "source": "derived" }, "source_filings": [ { "role": "annual", "current": false, "form": "10-K", "fiscal_year": 2025, "fiscal_period": "FY", "tag": "FY25", "period_end": "2025-12-31", "filed": "2026-02-20", "accession": "0001628280-26-010185", "url": "https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm", "source": "reported" }, { "role": "quarterly", "current": true, "form": "10-Q", "fiscal_year": 2026, "fiscal_period": "Q2", "tag": "FY26Q2", "period_end": "2026-06-30", "filed": "2026-07-28", "accession": "0001628280-26-050134", "url": "https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm", "source": "derived" } ] }